Loading news...
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Myriad announces FDA approval for the MyChoice CDx Test as the Companion Diagnostic for Zejula, a PARP inhibitor from GSK, for patients with ovarian cancer
Myriad Genetics delivered a solid Q4 2025 earnings beat, with positive adjusted EPS and strong test volume growth despite modest revenue decline. MYGN's core franchises—Prolaris and hereditary cancer—showed resilience, offsetting reimbursement headwinds in mental health and weakness in prenatal testing. Cost-cutting drove sharply lower operating expenses and narrowed losses, while gross margins remained stable at 70%, signaling operational stabilization.
Myriad Genetics jumps 21% after Q4 earnings beat estimates by 350% and revenues top forecasts, even as gross margin slips and mental health sales decline.
Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript
The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Myriad Genetics (MYGN) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.03 per share a year ago.
Highl ights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind 1 of $8.1 million. Full year 2025 revenue of $824.5 million decreased 2% year-over-year.
SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced the publication of the analytical validation of the FirstGene ® Multiple Prenatal Screen in Clinical Chemistry. The study showed that each component of the test had exceptional sensitivity and specificity.
Besides Wall Street's top-and-bottom-line estimates for Myriad (MYGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
SALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular testing and precision medicine, will hold its fourth quarter and full year 2025 earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026. The company's quarterly earnings will be released the same day after the market closes.
Myriad Genetics, Inc. (NASDAQ: MYGN - Get Free Report) has earned a consensus rating of "Hold" from the thirteen brokerages that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. The
AMH Equity Ltd increased its holdings in Myriad Genetics, Inc. (NASDAQ: MYGN) by 33.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 400,000 shares of the company's stock after buying an additional 100,000 shares during the
Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Myriad Genetics, Inc. (NASDAQ: MYGN - Get Free Report) has received a consensus recommendation of "Hold" from the fourteen analysts that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and four have assigned a buy recommendation to the company. The
Myriad announced select unaudited preliminary results for the 4th quarter and full year ended Dec. 31, 2025, provided full year 2026 financial guidance.
Myriad Genetics, Inc. (NASDAQ: MYGN - Get Free Report)'s stock price passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $6.52 and traded as high as $6.55. Myriad Genetics shares last traded at $6.52, with a volume of 1,175,254 shares traded. Analysts Set New Price Targets
SALT LAKE CITY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Sam Raha, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, at 5:15 pm PT (8:15 pm ET).
MYGN shows growth potential from new genetic test launches and a refreshed CCC strategy, but revenue pressure from GeneSight coverage loss remains a drag.